2. Cell Cycle/DNA Damage Vitamin D Related/Nuclear Receptor Metabolic Enzyme/Protease
  3. PPAR
  4. T0070907

T0070907 is a potent PPARγ antagonist with a Ki of 1 nM.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 313516-66-4

Tamaño Precio Stock Cantidad
Muestra gratis (0.1 - 0.2 mg)   Solicite ahora  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 En stock
Solution
10 mM * 1 mL in DMSO En stock
Solid
5 mg En stock
10 mg En stock
25 mg En stock
50 mg En stock
100 mg En stock
200 mg   Obtener un presupuesto  
500 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 42 publication(s) in Google Scholar

Other Forms of T0070907:

T0070907 Related Antibodies

Top Publications Citing Use of Products

42 Publications Citing Use of MCE T0070907

Cell Proliferation/Viability Assay
RT-PCR
In Vivo Efficacy Study
WB
Flow Cytometry

    T0070907 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 10;16(1):8215.  [Abstract]

    NECTIN4 mRNA levels in RT112 cells treated with 1 μM Rosiglitazone and T0070907 (T007) for 72 h.

    T0070907 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 10;16(1):8215.  [Abstract]

    T0070907 (0.5-2.5 μM; 72 h). Western blot for NECTIN4 and HPGD in RT112 cells treated with T0070907, Rosiglitazone, and Pioglitazone at indicated concentrations for 72 h.

    T0070907 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 10;16(1):8215.  [Abstract]

    NECTIN4 surface staining in RT112 cells treated with 1 μM Rosiglitazone and T0070907 for 72 h.

    T0070907 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 11:e08957.  [Abstract]

    T0070907 (10 µM; 1 µL per side; microinjected into the mPFC). The social interaction ratio of mice from control, SUS-vehicle, SUS-vehicle-pioglitazone, SUS-T0070907-pioglitazone groups.

    T0070907 purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2024 Apr:102:105079.  [Abstract]

    T0070907 (0-15 μM; 24 h). Viability of HepG2 cells treated with 400 μM PA and indicated concentrations of T0070907 for 24 h.

    T0070907 purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2996-3005.  [Abstract]

    HT22 cells were pretreated with the indicated inhibitors (CDDO (Bardoxolone, HY-14909); T0070907 (HY-13202); Troglitazone (HY-50935 ); TPCA-1 (HY-10074); JAKi; STAT3i; AV-412 (HY-10346); and MK2206 (HY-10358)) and then treated with T/Z, T/S/Z, T/C/Z for 9 h or Glutamate, Erastin (T: 20 ng/ml; Z: 50 μM; S: 20 nM; C: 1 μg/ml; Glutamate: 50 mM; Erastin 10 μM) for 12 h. Cell viability was measured by CellTiterGlo assay.

    Ver todos los productos específicos de isoformas PPAR:

    Ver todas las isoformas
    PPARα PPARβ/δ PPARγ PPAR PPARδ

    • Actividad biológica

    • Protocolo

    • Pureza y Documentación

    • Referencias

    • Revisión del cliente

    Descripciòn

    T0070907 is a potent PPARγ antagonist with a Ki of 1 nM.

    IC50 & Target[4]

    PPARγ

    1 nM (Ki)

    PPARδ

    1.8 μM (Ki)

    PPARα

    0.85 μM (Ki)

    Cellular Effect
    Cell Line Type Value Description References
    BMDM IC50
    0.067 μM
    Compound: T007; T0070907
    Inhibition of osteoclastogenesis in C57BL/6J mouse Bone marrow macrophage cells assessed as inhibition of RANKL-stimulated osteoclast formation measured after 6 days by tartrate-resistant acid phosphatase (TRAP) staining assay
    Inhibition of osteoclastogenesis in C57BL/6J mouse Bone marrow macrophage cells assessed as inhibition of RANKL-stimulated osteoclast formation measured after 6 days by tartrate-resistant acid phosphatase (TRAP) staining assay
    		[PMID: 39185622]
    In Vitro

    T0070907 (50 μM) pre-treatment impairs repair of IR-induced DNA DSBs in both ME-180 and SiHa cells treated with irradiated (4 Gy). T0070907 (0-50 μM) significantly decreases the levels of DNA-PKcs and RAD51 proteins in ME-180 and SiHa cells[1]. T0070907 (50 μM) treatment reduces the levels of α- and β-tubulin protein in a time-dependent manner, decreases the synthesis of DNA, and prevents the radiation-induced alterations in the cell cycle regulatory proteins of ME180 and SiHa cells[2]. T0070907 (10 μM) has cytotoxicity in an adipocyte-specific and PPARγ-independent manner. T0070907 increases oxidative stress in immature adipocytes[3]. T0070907 (1 μM) blocks the induction of adipogenesis by various treatments of the adipogenic cell line 3T3-L1. T0070907 covalently modifies PPAR on cysteine 313 in helix 3 of human PPAR 2[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    T0070907 Related Antibodies
    Peso molecular

    277.66

    Fòrmula

    C12H8ClN3O3
    No. CAS
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    ClC1=C(C=C(C=C1)[N+]([O-])=O)C(NC2=CC=NC=C2)=O
    Envío

    Room temperature in continental US; may vary elsewhere.
    Almacenamiento
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvente y solubilidad
    In Vitro: 

    DMSO : 62.5 mg/mL (225.10 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : < 0.1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.6015 mL 18.0076 mL 36.0153 mL
    5 mM 0.7203 mL 3.6015 mL 7.2031 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Calculadora de molaridad

    • Calculadora de dilución

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 1 mg/mL (3.60 mM); Clear solution

      This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 1 mg/mL (3.60 mM); Clear solution

      This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Pureza y Documentación

    Purity: 99.98%

    SDS (393 KB)

    COA (247 KB) LCMS (96 KB)

    Instrucciones de manejo (2659 KB)
    Referencias
    Ensayo de quinasas
    [4]

    To determine the binding affinity of T0070907 to the PPARs, scintillation proximity assay (SPA) is performed with the following modifications. A 90 μL reaction contains SPA buffer (10 mM K2HPO4, 10 mM KH2PO4, 2 mM EDTA, 50 mM NaCl, 1 mM dithiothreitol, 2 mM CHAPS, 10% (v/v) glycerol, pH 7.1), 50 ng of GST-PPAR (or 150 ng of GST-PPAR), 5 nM 3H-labeled radioligands, and 5 μL of T0070907 in Me2SO. After incubation for 1 h at room temperature, 10 μL of polylysine-coated SPA beads (at 20 mg/mL in SPA buffer) are added, and the mixture is incubated for 1 h before reading in Packard Topcount. [3H]Rosiglitazone is used for PPAR, and [3H]GW2433 is used for PPAR and PPAR.

    MCE no ha confirmado la precisión de estos métodos independientemente. Son solo para referencia.
    Referencias

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.6015 mL 18.0076 mL 36.0153 mL 90.0382 mL
    5 mM 0.7203 mL 3.6015 mL 7.2031 mL 18.0076 mL
    10 mM 0.3602 mL 1.8008 mL 3.6015 mL 9.0038 mL
    15 mM 0.2401 mL 1.2005 mL 2.4010 mL 6.0025 mL
    20 mM 0.1801 mL 0.9004 mL 1.8008 mL 4.5019 mL
    25 mM 0.1441 mL 0.7203 mL 1.4406 mL 3.6015 mL
    30 mM 0.1201 mL 0.6003 mL 1.2005 mL 3.0013 mL
    40 mM 0.0900 mL 0.4502 mL 0.9004 mL 2.2510 mL
    50 mM 0.0720 mL 0.3602 mL 0.7203 mL 1.8008 mL
    60 mM 0.0600 mL 0.3001 mL 0.6003 mL 1.5006 mL
    80 mM 0.0450 mL 0.2251 mL 0.4502 mL 1.1255 mL
    100 mM 0.0360 mL 0.1801 mL 0.3602 mL 0.9004 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    T0070907 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    T0070907313516-66-4T 0070907T-0070907PPARPeroxisome proliferator-activated receptorsInhibitorinhibitorinhibit

    Productos vistos recientemente:

    Consulta en línea

    Your information is safe with us. * Required Fields.

    Nombre del producto

    		  

    Requested Quantity *

    Nombre del solicitante *

    		 

    Saludo

    Direcciòn del E-mail *

    		 

    Número de teléfono *

    Department

    		 

    Nombre de la Organizaciòn *

    City

    Provincia

    Country or Region *

    		      

    Observaciones

    Consulta para venta a granel

    Inquiry Information

    Nombre del producto:
    T0070907
    Cat. No.:
    HY-13202
    Cantidad:
    MCE Japan Authorized Agent:

    Revisión del cliente

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Nombre del producto

    		  

    Lot #

    Nombre del solicitante *

    		 

    Direcciòn del E-mail *

    Número de teléfono

    		 

    Department *

    Nombre de la Organizaciòn *

    		 

    Country or Region *

    Observaciones

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.